Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001055691 | SCV001220091 | pathogenic | not provided | 2024-02-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Phe20Alafs*8) in the SLC12A3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC12A3 are known to be pathogenic (PMID: 20848653, 22009145, 25841442). This variant is present in population databases (rs758683818, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with clinical features of Gitelman syndrome (PMID: 31285285). ClinVar contains an entry for this variant (Variation ID: 851316). For these reasons, this variant has been classified as Pathogenic. |
New York Genome Center | RCV001832505 | SCV002097874 | likely pathogenic | Familial hypokalemia-hypomagnesemia | 2020-06-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004678925 | SCV005167301 | likely pathogenic | Inborn genetic diseases | 2024-05-17 | criteria provided, single submitter | clinical testing | The c.56_57dupGC (p.F20Afs*8) alteration, located in exon 1 (coding exon 1) of the SLC12A3 gene, consists of a duplication of GC at position 56, causing a translational frameshift with a predicted alternate stop codon after 8 amino acids. The predicted stop codon occurs in the 5' end of the SLC12A3 gene. Premature termination codons in the 5’ end of a gene have been reported to escape nonsense-mediated mRNA decay and/or lead to re-initiation (Rivas, 2015; Lindeboom, 2016; Rhee, 2017). Direct evidence for this alteration is unavailable; however, premature termination codons are typically deleterious in nature. Based on data from gnomAD, the GCGC allele has an overall frequency of 0.001% (2/282296) total alleles studied. The highest observed frequency was 0.014% (1/7216) of Other alleles. This variant has been reported homozygous and in conjunction with another SLC12A3 variant in individuals genetically diagnosed with Gitelman syndrome; however, clinical details were limited (Blanchard, 2015; Alexandru, 2020). Based on the available evidence, this alteration is classified as likely pathogenic. |
Fulgent Genetics, |
RCV001832505 | SCV005639132 | pathogenic | Familial hypokalemia-hypomagnesemia | 2024-01-06 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001832505 | SCV002089317 | pathogenic | Familial hypokalemia-hypomagnesemia | 2021-09-01 | no assertion criteria provided | clinical testing |